| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| NEUTRAL | NEUTRAL | NEUTRAL | NEUTRAL | NEUTRAL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | N/A | N/A | N/A | N/A | N/A |
| MA10 | N/A | N/A | N/A | N/A | N/A |
| MA20 | N/A | N/A | N/A | N/A | N/A |
| MA50 | N/A | N/A | N/A | N/A | N/A |
| MA100 | N/A | N/A | N/A | N/A | N/A |
| MA200 | N/A | N/A | N/A | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | N/A | N/A | N/A | N/A | N/A |
| RSI | N/A | N/A | N/A | N/A | N/A |
| STOCH | N/A | N/A | N/A | N/A | N/A |
| WILL %R | N/A | N/A | N/A | N/A | N/A |
| CCI | N/A | N/A | N/A | N/A | N/A |
|
Wednesday, January 07, 2026 06:47 AM
Investing.com -- FibroGen Inc (NASDAQ:FGEN) stock rose 5% on Wednesday after the company announced it would rebrand as Kyntra Bio, reflecting its sharpened focus on oncology and rare disease therapies ...
|
|
Wednesday, January 07, 2026 05:02 AM
Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare diseaseKyntra Bio will begin trading on Nasdaq ...
|
|
Wednesday, January 07, 2026 05:00 AM
Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare diseaseKyntra Bio will begin trading on Nasdaq un ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 13/01/26 | 9.17 | 9.235 | 9.17 | 9.235 | 9,000 |
| 12/01/26 | 9.10 | 9.21 | 9.02 | 9.07 | 20,045 |
|
|
||||
|
|
||||
|
|